UBC's Blog

UBC is committed to sharing ideas & insights with the pharmaceutical & biotech industry to address the full product lifecycle & support the development & commercialization of safe & effective products.

 

, Vice President, Business Development - January 09, 2013
We all welcomed the news when the U.S. Food and Drug Administration (FDA) approved Gattex® (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (SBS) who are...
, Vice President, Global Pharmaceutical Business Development - January 02, 2013
While we would all like highly customized programs for our favorite products, the fact is not all products require a full spectrum of specialized services. Sometimes a product just needs a little something extra… You see, not every...
UBC - December 31, 2012
It’s been our privilege to be a part of your work this past year.  We appreciate the opportunity to support your products.  On behalf of all of us at UBC, we look forward to working with you in 2013!
, Director, Business Development - December 21, 2012
If changes to the healthcare landscape have you puzzled, you’re not alone.  In an environment where there seem to be more questions than answers, our Healthcare Reform experts analyzed new healthcare regulations from a...
UBC - December 21, 2012
NPS Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Gattex® (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (...

Pages